Charles Fuchs, an oncology expert, has been appointed chief medical officer at Tubulis GmbH. He will provide strategic clinical and medical leadership as Tubulis moves its lead products, TUB-040 and TUB-030, into later stage clinical evaluation and expands its ADC pipeline.
Dr Fuchs will be based in Tubulis’ Cambridge, US, office. He previously led global oncology and haematology product development at Genentech and Roche. Before joining the pharmaceutical industry, Dr Fuchs was cancer center director at Yale Cancer Center and Smilow Cancer Hospital, US. At Dana‑Farber Cancer Institute and Harvard Medical School, he built research programmes in gastrointestinal cancers and cancer epidemiology. Dr Fuchs is board certified in medical oncology, holding an MD from Harvard Medical School and a master of public health from the Harvard T.H. Chan School of Public Health.
Tubulis announced the appointment on 8 January 2026.
Copyright 2026 Evernow Publishing Ltd.